You are here: Industry Insights > Wuxi Biologics

News List

WuXi Biologics Records Excellent Interim Results WuXi Biologics
August 18, 2020
WuXi Biologics is pleased to announce its unaudited interim results for the six months ended June 30, 2020.
WuXi Biologics to Open Clinical Mfg. Facility in Cranbury, NJ contractpharma
June 10, 2020
Will install total 6000 L bioreactors, Process Development (PD), Quality Control (QC) labs, along with supporting functions.
WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States WuXi Biologics
June 09, 2020
WuXi Biologics announced that it has signed a 10-year lease for a clinical manufacturing facility (MFG18) in Cranbury, New Jersey.
WuXi Biologics Expands U.S. Footprint contractpharma
May 21, 2020
Closes land deal to build 107,000-sq.-ft., state-of-the-art biologics production facility in Worcester, MA.
WuXi Biologics Closes Land Deal to Build State-of-the-Art Biologics Production Facility in the US Wuxi Biologics
May 20, 2020
WuXi Biologics announced today the successful signing of a land deal for WuXi Biologics’ clinical and commercial manufacturing facility (MFG11) in Worcester at The Reactory, a 46-acre master-planned biomanufacturing campus.
WuXi Biologics Completes PFS Filling at Robotic Aseptic Filling Facility contractpharma
April 30, 2020
Successfully completes the filling of two batches of pre-filled syringes using robotic filling isolator.
WuXi Biologics Successfully Completes PFS Filling at its Robotic Aseptic Filling Facility PharmaSources.com
April 29, 2020
First GMP facility in WuXi Biologics to use robotic aseptic filling line for biologics; Demonstrated diverse and flexible aseptic filling capability while maintaining high-quality and controlled filling accuracy as well as aseptic assurance.
WuXi Biologics (Suzhou) Successfully Passed First EMA GMP Inspection prnasia
April 14, 2020
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platform, announced that WuXi Biologics (Suzhou) Co., Ltd. has successfully passed its first GMP inspection by the European Medicines Agency (EMA), with
WuXi Biologics (Suzhou) Successfully Passed First EMA GMP Inspection Wuxi Biologics
April 14, 2020
WuXi Biologics, a global company with leading open-access biologics technology platform, announced that WuXi Biologics (Suzhou) Co., Ltd. has successfully passed its first GMP inspection by the European Medicines Agency (EMA).
WuXi Biologics Achieved Remarkable Results in 2019 Wuxi Biologics
March 27, 2020
WuXi Biologics Achieved Remarkable Results in 2019, and is working to defeat COVID-19.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page